

Evonik to support Chinese anti-dumping investigations for methionine

On April 10, the Ministry of Commerce of the People's Republic of China announced anti-dumping investigations concerning the import of the essential amino acid and feed additive methionine from Japan, Malaysia and Singapore. The period considered for possible dumping is the calendar year 2018. In addition, it will also be analyzed whether domestic industry suffered losses in the calendar years 2016 to 2018 in this context. The investigation is said to be completed by April 10, 2020.

Evonik fully supports the investigation by the Chinese authorities and will provide competent bodies with all the necessary information and data. The company will cooperate fully in the ongoing investigation, while being confident with respect to its outcome.

The specialty chemicals company is one of the world's leading manufacturers of the essential amino acid DL-methionine, which the company markets under the brand name MetAMINO®.

Evonik manufactures MetAMINO® at four locations in Antwerp (Belgium), Mobile (Alabama, USA), Singapore and Wesseling (Germany). The largest plant is located in Antwerp. Relying on this production network, Evonik supplies customers in more than 120 countries, ensuring a structurally reliable supply of methionine on a global basis – regardless of geographic location.

The essential amino acid methionine needs to be ingested with the feed. As a feed additive, it contributes to efficient, healthy and more sustainable nutrition of farm animals, especially poultry and pigs. April 11, 2019

Tim Lange

Head of Investor Relations Phone +49 201 177-3150 tim.lange@evonik.com

Evonik Industries AG

Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Fax +49 201 177-3475 www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman
Dr. Werner Müller, Honorary Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel
Ute Wolf

Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474

Investor Relations News



About Evonik

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, innovative prowess and a trustful and performance—oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2018.

Disclaimer

In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.